APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

Part of paid clinical trials in San Francisco, California.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00027599
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • prostatic acid phosphatase-sargramostim fusion protein — BIOLOGICAL
  • sipuleucel-T — BIOLOGICAL
  • therapeutic autologous dendritic cells — BIOLOGICAL
  • in vitro-treated peripheral blood stem cell transplantation — PROCEDURE

Study Details

Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer. Biological therapies such as APC8015 use different ways to stimulate the immune system and stop cancer cells from growing. Monoclonal antibodies such as bevacizumab can locate tumor cells and kill them without harming normal cells. Combining monoclonal antibody therapy with biological therapy may kill more cancer cells.

Key Dates

First listed
May 7, 2003
Start date
Dec 31, 2001
Status verified
Dec 2003
Primary completion
Jul 31, 2007

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm I
    Autologous dendritic cells (DCs) are harvested and pulsed with prostatic acid phosphatase-sargramostim fusion protein to produce APC8015 (Provenge). Patients receive APC8015 IV over 30 minutes and bevacizumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days for 3 courses. Patients continue to receive bevacizumab alone every 14 days in the absence of disease progression or unacceptable toxicity.

Locations (1)

FacilityCityStateZIPSite coordinators
UCSF Comprehensive Cancer CenterSan FranciscoCalifornia94115-

Find similar trials in San Francisco, CA

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
UCSF Comprehensive Cancer Center· San Francisco, CA

Related Studies